{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:24:04Z","timestamp":1754112244936,"version":"3.37.3"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100017005","name":"Deutsche Hochdruckliga","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010578","name":"Deutsche Gesellschaft f\u00fcr Kardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Arterial hypertension is associated with increased cardiovascular morbidity and mortality. Although blood pressure-lowering therapies significantly reduce the risk of major cardiovascular events, blood pressure control remains unsatisfactorily low. Several device-based antihypertensive therapies have been investigated in patients with treatment-resistant hypertension and in patients unable or unwilling to adhere to antihypertensive medication. As the field of device-based therapies is subject to constant change, this review aims at providing an up-to-date overview of different device-based approaches for the treatment of hypertension. These approaches target the sympathetic nervous system (renal denervation, baroreflex amplification therapy, baroreflex activation therapy, and carotid body ablation) or alter mechanical arterial properties by creating an iliac arteriovenous fistula. Notably, the use of all of these treatment options is not recommended for the routine treatment of hypertension by current guidelines but should be investigated in the context of controlled clinical studies.<\/jats:p>","DOI":"10.1093\/ajh\/hpz161","type":"journal-article","created":{"date-parts":[[2019,9,29]],"date-time":"2019-09-29T11:21:45Z","timestamp":1569756105000},"page":"10-18","source":"Crossref","is-referenced-by-count":8,"title":["The Current Status of Devices for the Treatment of Resistant Hypertension"],"prefix":"10.1093","volume":"33","author":[{"given":"Michael","family":"Kunz","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes, Saarland University, Homburg\/Saar, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-9556","authenticated-orcid":false,"given":"Lucas","family":"Lauder","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes, Saarland University, Homburg\/Saar, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Ewen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes, Saarland University, Homburg\/Saar, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes, Saarland University, Homburg\/Saar, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes, Saarland University, Homburg\/Saar, Germany"},{"name":"Institute for Medical Engineering and Science, Massachusetts Institute of Technology , Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"2022101115063294900_CIT0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"2022101115063294900_CIT0002","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2022101115063294900_CIT0003","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"2022101115063294900_CIT0004","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","article-title":"Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries","volume":"310","author":"Chow","year":"2013","journal-title":"JAMA"},{"key":"2022101115063294900_CIT0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"key":"2022101115063294900_CIT0006","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/eurheartj\/ehx215","article-title":"Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future","volume":"38","author":"Mahfoud","year":"2017","journal-title":"Eur Heart J"},{"key":"2022101115063294900_CIT0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J Hum Hypertens"},{"key":"2022101115063294900_CIT0008","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-019-01468-0","article-title":"Patient preference for therapies in hypertension: a cross-sectional survey of German patients","author":"Schmieder","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022101115063294900_CIT0009","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/eurheartj\/ehv192","article-title":"Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design","volume":"36","author":"Mahfoud","year":"2015","journal-title":"Eur Heart J"},{"key":"2022101115063294900_CIT0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00392-018-1299-y","article-title":"Hypertension: history and development of established and novel treatments","volume":"107","author":"Wolf","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2022101115063294900_CIT0011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1152\/japplphysiol.00832.2009","article-title":"The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management","volume":"108","author":"Esler","year":"2010","journal-title":"J Appl Physiol (1985)"},{"key":"2022101115063294900_CIT0012","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ijcard.2014.09.138","article-title":"Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension","volume":"177","author":"Grassi","year":"2014","journal-title":"Int J Cardiol"},{"key":"2022101115063294900_CIT0013","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0002-9343(48)90397-0","article-title":"Surgical treatment of hypertension","volume":"4","author":"Smithwick","year":"1948","journal-title":"Am J Med"},{"key":"2022101115063294900_CIT0014","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCRESAHA.115.302522","article-title":"Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?","volume":"115","author":"B\u00f6hm","year":"2014","journal-title":"Circ Res"},{"key":"2022101115063294900_CIT0015","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4244\/EIJV9I9A175","article-title":"What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension","volume":"9","author":"Tsioufis","year":"2014","journal-title":"EuroIntervention"},{"key":"2022101115063294900_CIT0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11886-019-1164-2","article-title":"Renal denervation: is it ready for prime time?","volume":"21","author":"Lauder","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2022101115063294900_CIT0017","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(13)62192-3","article-title":"Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study","volume":"383","author":"Krum","year":"2014","journal-title":"Lancet"},{"key":"2022101115063294900_CIT0018","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"key":"2022101115063294900_CIT0019","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/jhh.2013.88","article-title":"Blood pressure changes after renal denervation at 10 European expert centers","volume":"28","author":"Persu","year":"2014","journal-title":"J Hum Hypertens"},{"key":"2022101115063294900_CIT0020","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/eurheartj\/ehw016","article-title":"CardioPulse articles","volume":"37","author":"Oparil","year":"2016","journal-title":"Eur Heart J"},{"key":"2022101115063294900_CIT0021","first-page":"1101","article-title":"Interventional procedures and future drug therapy for hypertension","volume":"38","author":"Lobo","year":"2017","journal-title":"Eur Heart J"},{"key":"2022101115063294900_CIT0022","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jash.2014.12.002","article-title":"Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the \u201cend of the road\u201d for renal denervation?","volume":"9","author":"Epstein","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"2022101115063294900_CIT0023","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurheartj\/ehu441","article-title":"Predictors of blood pressure response in the SYMPLICITY HTN-3 trial","volume":"36","author":"Kandzari","year":"2015","journal-title":"Eur Heart J"},{"key":"2022101115063294900_CIT0024","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial","volume":"385","author":"Azizi","year":"2015","journal-title":"Lancet"},{"key":"2022101115063294900_CIT0025","doi-asserted-by":"crossref","first-page":"H402","DOI":"10.1152\/ajpheart.00372.2010","article-title":"Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex","volume":"299","author":"Lohmeier","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022101115063294900_CIT0026","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.4244\/EIJY18M07_1","article-title":"Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications","volume":"14","author":"Ewen","year":"2018","journal-title":"EuroIntervention"},{"key":"2022101115063294900_CIT0027","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ahj.2015.08.021","article-title":"The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications","volume":"171","author":"Kandzari","year":"2016","journal-title":"Am Heart J"},{"key":"2022101115063294900_CIT0028","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"2022101115063294900_CIT0029","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/eurheartj\/ehy871","article-title":"Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial","volume":"40","author":"B\u00f6hm","year":"2019","journal-title":"Eur Heart J"},{"key":"2022101115063294900_CIT0030","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"2022101115063294900_CIT0031","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1161\/CIRCULATIONAHA.119.040451","article-title":"Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO Trial","volume":"139","author":"Azizi","year":"2019","journal-title":"Circulation"},{"key":"2022101115063294900_CIT0032","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurheartj\/ehz118","article-title":"Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry","author":"Mahfoud","year":"2019","journal-title":"Eur Heart J"},{"key":"2022101115063294900_CIT0033","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1097\/HJH.0000000000001798","article-title":"Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis","volume":"36","author":"Kordalis","year":"2018","journal-title":"J Hypertens"},{"key":"2022101115063294900_CIT0034","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCULATIONAHA.118.037654","article-title":"A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN)","volume":"139","author":"Fengler","year":"2019","journal-title":"Circulation"},{"key":"2022101115063294900_CIT0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11906-018-0840-8","article-title":"Endovascular baroreflex amplification for resistant hypertension","volume":"20","author":"van Kleef","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"2022101115063294900_CIT0036","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/HYPERTENSIONAHA.107.095216","article-title":"Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure","volume":"50","author":"Zucker","year":"2007","journal-title":"Hypertension"},{"key":"2022101115063294900_CIT0037","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/000331976902000405","article-title":"The effect of carotid sinus nerve stimulation on cardiovascular dynamics in man","volume":"20","author":"Rothfeld","year":"1969","journal-title":"Angiology"},{"key":"2022101115063294900_CIT0038","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejvs.2006.11.025","article-title":"An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension","volume":"33","author":"Tordoir","year":"2007","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2022101115063294900_CIT0039","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/jhh.2013.139","article-title":"Baroreflex activation therapy in hypertension","volume":"28","author":"Gassler","year":"2014","journal-title":"J Hum Hypertens"},{"key":"2022101115063294900_CIT0040","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jacc.2010.03.089","article-title":"Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study","volume":"56","author":"Scheffers","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022101115063294900_CIT0041","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2022101115063294900_CIT0042","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/HYPERTENSIONAHA.114.04492","article-title":"Bilateral or unilateral stimulation for baroreflex activation therapy","volume":"65","author":"de Leeuw","year":"2015","journal-title":"Hypertension"},{"key":"2022101115063294900_CIT0043","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/HYPERTENSIONAHA.117.09086","article-title":"Sustained reduction of blood pressure with baroreceptor activation therapy: results of the 6-year open follow-up","volume":"69","author":"de Leeuw","year":"2017","journal-title":"Hypertension"},{"key":"2022101115063294900_CIT0044","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jash.2012.04.004","article-title":"Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial","volume":"6","author":"Hoppe","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"2022101115063294900_CIT0045","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/S0140-6736(17)32337-1","article-title":"Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study","volume":"390","author":"Spiering","year":"2017","journal-title":"Lancet"},{"key":"2022101115063294900_CIT0046","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1152\/physrev.1994.74.3.543","article-title":"Peripheral chemoreceptors and cardiovascular regulation","volume":"74","author":"Marshall","year":"1994","journal-title":"Physiol Rev"},{"key":"2022101115063294900_CIT0047","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/hr.2011.209","article-title":"Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension","volume":"35","author":"Si\u0144ski","year":"2012","journal-title":"Hypertens Res"},{"key":"2022101115063294900_CIT0048","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1161\/HYPERTENSIONAHA.108.127530","article-title":"Cardiovascular regulation during apnea in elite divers","volume":"53","author":"Heusser","year":"2009","journal-title":"Hypertension"},{"key":"2022101115063294900_CIT0049","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/HYPERTENSIONAHA.111.00064","article-title":"The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases","volume":"61","author":"Paton","year":"2013","journal-title":"Hypertension"},{"key":"2022101115063294900_CIT0050","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1113\/JP272708","article-title":"Carotid sinus denervation ameliorates renovascular hypertension in adult Wistar rats","volume":"594","author":"Pijacka","year":"2016","journal-title":"J Physiol"},{"key":"2022101115063294900_CIT0051","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacbts.2016.06.004","article-title":"Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial","volume":"1","author":"Narkiewicz","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2022101115063294900_CIT0052","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy565.1416","article-title":"1416 Transvenous carotid body ablation for resistant hypertension: main results of a multicentre safety and proof-of-principle cohort study","volume":"39","author":"Schlaich","year":"2018","journal-title":"Eur Heart J"},{"key":"2022101115063294900_CIT0053","doi-asserted-by":"crossref","first-page":"e011183","DOI":"10.1161\/JAHA.118.011183","article-title":"Effects of arteriovenous fistula on blood pressure in patients with end-stage renal disease: a systematic meta-analysis","volume":"8","author":"Scholz","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022101115063294900_CIT0054","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11906-015-0585-6","article-title":"Central iliac arteriovenous anastomosis for hypertension: targeting mechanical aspects of the circulation","volume":"17","author":"Kapil","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"2022101115063294900_CIT0055","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ccd.25707","article-title":"The ROX coupler: creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature","volume":"85","author":"Foran","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"key":"2022101115063294900_CIT0056","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(14)62053-5","article-title":"Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial","volume":"385","author":"Lobo","year":"2015","journal-title":"Lancet"},{"key":"2022101115063294900_CIT0057","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jvs.2013.10.069","article-title":"Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension","volume":"59","author":"Faul","year":"2014","journal-title":"J Vasc Surg"},{"key":"2022101115063294900_CIT0058","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1161\/HYPERTENSIONAHA.117.10142","article-title":"Central iliac arteriovenous anastomosis for uncontrolled hypertension: one-year results from the ROX CONTROL HTN trial","volume":"70","author":"Lobo","year":"2017","journal-title":"Hypertension"},{"key":"2022101115063294900_CIT0059","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.116.004234","article-title":"Effect of arteriovenous anastomosis on blood pressure reduction in patients with isolated systolic hypertension compared with combined hypertension","volume":"5","author":"Ott","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2022101115063294900_CIT0060","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00392-018-1395-z","article-title":"Secondary rise in blood pressure and leg swelling after central arteriovenous anastomosis","volume":"108","author":"Lauder","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022101115063294900_CIT0061","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1093\/eurheartj\/ehy078","article-title":"Real-time left ventricular pressure-volume loops during percutaneous central arteriovenous anastomosis","volume":"39","author":"Ewen","year":"2018","journal-title":"Eur Heart J"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpz161\/30297690\/hpz161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/33\/1\/10\/46440198\/hpz161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/33\/1\/10\/46440198\/hpz161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T15:08:31Z","timestamp":1665500911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/33\/1\/10\/5579377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,10,1]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpz161","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"type":"print","value":"0895-7061"},{"type":"electronic","value":"1941-7225"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,10,1]]}}}